Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals will present new data on the combination of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV) at the EASL Congress 2024. The presentations will showcase antiviral efficacy, including SVR12 data from the ongoing Phase 2 HCV trial's lead-in cohort. Preclinical data highlight bemnifosbuvir's high resistance barrier and pharmacokinetics, and ruzasvir's low risk of drug-drug interactions. The full dataset will be available on the EASL Congress website on June 5, 2024. HCV remains a significant health issue in the U.S., with over 2 million chronic cases and annual diagnoses outpacing cure rates.
Atea Pharmaceuticals reported Q1 2024 financial results, highlighting key developments in their COVID-19 and HCV treatment trials. The company completed enrollment in the global Phase 3 SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients, with results expected in H2 2024. Additionally, they are progressing in their Phase 2 trial for HCV treatment with bemnifosbuvir and ruzasvir, also expecting results in H2 2024. Financially, Atea reported a net loss of $63.2 million, up from $35.5 million YoY, primarily due to increased R&D expenses. Cash and equivalents stood at $541.5 million, down from $578.1 million at the end of 2023.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a conference call on May 14, 2024, to report financial results for the first quarter ended March 31, 2024, and provide a business update. Participants can access the live webcast on the company's Investor Relations website. Telephone registration is required for participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.